Psoriatic Arthritis News and Research

RSS

Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Centocor Ortho Biotech Inc. announced today that it has filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) requesting the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.

29 Dec 2010

Golimumab with methotrexate improves markers of inflammation and structural damage in RA patients

Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of golimumab 50 mg plus methotrexate resulted in statistically significant improvements in markers of inflammation and structural damage in patients with active rheumatoid arthritis (RA) compared with placebo plus methotrexate.

30 Nov 2010

IFPA announces winner of Under the Spotlight Award for psoriasis documentary

125 million people worldwide suffer from psoriasis and the hardships this difficult disease brings. Today, on the International Day of Tolerance we are very proud to announce the winner of the 1st Under the Spotlight Award for Best International Documentary on Psoriasis.

16 Nov 2010

SIMPONI injection improves inflammation, structural damage in RA patients

Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of SIMPONI (golimumab) 50 mg plus methotrexate resulted in statistically significant improvements in markers of inflammation and structural damage in patients with active rheumatoid arthritis (RA) compared with placebo plus methotrexate.

9 Nov 2010

Study suggests bacterial products contribute to autoimmune diseases

Researchers are using 21st century technologies to investigate the century old hypothesis that certain autoimmune diseases, including rheumatoid arthritis, are caused by bacteria living in the human body and will present their initial data this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Anti-TNF therapies may reduce Alzheimer's risk among people with rheumatoid arthritis

Anti-TNF therapies commonly used to treat rheumatoid arthritis have been found to potentially reduce the risk of developing Alzheimer's dementia among people with rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

Celgene Corporation announced non-GAAP net income of $349.9 million, or non-GAAP diluted earnings per share of $0.75 for the quarter ended September 30, 2010.

28 Oct 2010

New global event focuses on childhood psoriasis

October 29 is World Psoriasis Day. Conceived by patients for patients, World Psoriasis Day is a truly global event focusing on the burden of living with psoriasis. There are more than 125 million people with psoriasis/psoriatic arthritis in the world. Many are children. Psoriasis is a severe chronic inflammatory disease that effects all ages, genders, races and ethnicities.

28 Oct 2010

IPC investigating relationship between BMI and severity of psoriasis in childhood

As people around the world get ready to participate in events for World Psoriasis Day on October 29, the International Psoriasis Council (IPC) is nearing completion with enrollment in a multi-center study on the relationship between obesity and psoriasis in children. The theme of this year’s World Psoriasis Day is childhood psoriasis.

28 Oct 2010

Survey highlights emotional impact of psoriasis on school children

Almost half of children with psoriasis surveyed by the National Psoriasis Foundation report being bullied at least once in the last six months. The Psoriasis Foundation surveyed parents of kids with psoriatic disease and found that 44 percent of children have been bullied by their peers, and 38 percent of kids say the abuse was a direct result of their disease.

26 Oct 2010

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson today announced sales of $15.0 billion for the third quarter of 2010, a decrease of 0.7% as compared to the third quarter of 2009. Operational results increased 0.1% and the negative impact of currency was 0.8%. Domestic sales declined 2.5%, while international sales increased 1.1%, reflecting operational growth of 2.6% and a negative currency impact of 1.5%.

19 Oct 2010

Discovery of 4 new DNA 'hotspots' may aid in developing new therapies for psoriasis

Scientists at the University of Michigan Heath System and their collaborators have found four new DNA "hotspots" that may one day help guide new treatments for psoriasis, one of the most common autoimmune diseases in the country.

19 Oct 2010

PCE, NPF form partnership to provide education programs on psoriasis

Practicing Clinicians Exchange (PCE) has formed a partnership with the National Psoriasis Foundation (NPF) to provide continuing education programs to nurse practitioners (NPs) and physician assistants (PAs) throughout the United States.

19 Oct 2010

Discovery may aid in developing new psoriasis therapies

Scientists at the University of Michigan Heath System and their collaborators have found four new DNA “hotspots” that may one day help guide new treatments for psoriasis, one of the most common autoimmune diseases in the country.

18 Oct 2010

Questcor's H.P. Acthar Gel sNDA for infantile spasms receives FDA approval

Questcor Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved Questcor's supplemental new drug application (sNDA) for H.P. Acthar® Gel (repository corticotropin injection) in the treatment of infantile spasms (IS), an ultra-rare orphan disorder affecting approximately 2,000 American children annually. IS is a devastating and potentially life-threatening form of epilepsy seen in infancy and early childhood.

15 Oct 2010

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

Chelsea Therapeutics International, Ltd. has initiated enrollment in a multinational, 12-week, double-blind Phase II trial designed to compare the efficacy and tolerability of CH-4051 against methotrexate (MTX) in 250 patients with rheumatoid arthritis (RA) who are experiencing an inadequate response to MTX treatment.

27 Sep 2010

Researchers receive BioBank DNA samples to unveil psoriasis genetics

Millions of Americans struggling with psoriasis and psoriatic arthritis are one step closer to a cure with the release of the first National Psoriasis Victor Henschel BioBank DNA samples for use in research at the University of Michigan Health System; research that hopes to uncover the unknowns about the genetics of psoriasis and psoriatic arthritis.

3 Sep 2010

FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis

Chelsea Therapeutics International, Ltd. announced confirmation by the U.S. Food and Drug Administration (FDA) that its proposed Phase II protocol for CH-4051 in rheumatoid arthritis has been approved by the agency.

26 Aug 2010

Merck's SIMPONI anti-TNF therapy now reimbursed in New Brunswick, Nova Scotia and Alberta

Merck is pleased to announce that New Brunswick, Nova Scotia and Alberta are the first provinces in Canada to reimburse SIMPONI(golimumab) for the treatment of three different rheumatic conditions. SIMPONI, a subcutaneous anti-tumor necrosis factor therapy, is now reimbursed by the drug formularies of these three provinces for people living with moderately to severely active rheumatoid arthritis, moderately to severely active psoriatic arthritis and active ankylosing spondylitis.

17 Aug 2010

Avenue to Access provides free prescription-size tube of ZITHRANOL-RR to stable plaque psoriasis patients

During the month of August, people with a certain type of psoriasis have the chance to access free medicine through Avenue to Access. The program is designed to help individuals with mild-to-moderate stable plaque psoriasis access to a free prescription-size tube of ZITHRANOL-RR (anthralin, 1.2%) rapid release microcrystalline encapsulated cream.

16 Aug 2010

Psoriatic Arthritis News and Research

Further Reading

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Golimumab with methotrexate improves markers of inflammation and structural damage in RA patients

IFPA announces winner of Under the Spotlight Award for psoriasis documentary

SIMPONI injection improves inflammation, structural damage in RA patients

Study suggests bacterial products contribute to autoimmune diseases

Anti-TNF therapies may reduce Alzheimer's risk among people with rheumatoid arthritis

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

New global event focuses on childhood psoriasis

IPC investigating relationship between BMI and severity of psoriasis in childhood

Survey highlights emotional impact of psoriasis on school children

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Discovery of 4 new DNA 'hotspots' may aid in developing new therapies for psoriasis

PCE, NPF form partnership to provide education programs on psoriasis

Discovery may aid in developing new psoriasis therapies

Questcor's H.P. Acthar Gel sNDA for infantile spasms receives FDA approval

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

Researchers receive BioBank DNA samples to unveil psoriasis genetics

FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis

Merck's SIMPONI anti-TNF therapy now reimbursed in New Brunswick, Nova Scotia and Alberta

Avenue to Access provides free prescription-size tube of ZITHRANOL-RR to stable plaque psoriasis patients

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News